stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | — | 4 | 6 |
+8 more TTM periods Free account |
| (12.56%) | (17.16%) | (16.79%) | 19.90% | ||
| (11.76%) | (15.92%) | (15.53%) | 18.24% | ||
ROIC |
(233.22%) | (1,345.30%) | (1,668.70%) | 268.69% | |
Return on Tangible Assets |
(22.43%) | (32.18%) | (30.22%) | 29.07% | |
Average Days of Receivables |
0.00 | 0.00 | 29.15 | 8.70 | |
Free Cash Flow per Share |
(2.43) | (2.45) | (2.97) | 2.85 | |
Free Cash Flow |
(48.27) | (48.49) | (58.25) | 105.95 | |
Capital Expenditures |
(0.42) | (0.49) | (1.06) | (1.55) | |
| Other line items | |||||
Cash ROIC |
(8.96%) | (9.33%) | (10.27%) | 17.94% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 3.33 | 57.03 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.07) | 0.00 | 0.00 | (0.05) | |
Research and Development Expense of Revenue |
139.63% | 0.00% | 292.42% | 53.12% | |
Selling, General and Administrative Expense of Revenue |
67.60% | 0.00% | 140.13% | 19.20% | |
Share Based Compensation of Revenue |
41.95% | 0.00% | 78.45% | 11.76% | |
Operating CF/Net income |
0.78 | 0.58 | 0.67 | 1.24 | |
Depreciation/Fixed assets |
0.47 | 0.43 | 0.40 | 0.35 | |
Capex/Depreciation |
(0.26) | (0.31) | (0.68) | (1.03) | |
Revenue per Share |
2.77 | 0.00 | 1.69 | 6.56 | |
Operating CF per Share |
(2.41) | (2.42) | (2.91) | 2.89 | |
Capex per Share |
(0.02) | (0.02) | (0.05) | (0.04) | |
Capex to Sales |
0.01 | 0.00 | 0.03 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026